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Abstract 
Purpose: To investigate the role of the interleukin (IL)-33 and ST2 pathway in non-small cell lung 
cancer (NSCLC), and to further explore the critical relationships among inflammation, immunity, and 
cancer.  
Methods: From January 2014 to December 2015, paraffin-embedded sections of surgical specimens 
were obtained from 40 patients definitively diagnosed with NSCLC by pathological examination in 
Changzhou Wujin People's Hospital and Taicang Hospital of Traditional Chinese Medicine. Sections 
were further immunostained with antibodies directed against IL-33 and ST2 cardiac biomarker. 
Inflammatory reactions were determined by hematoxylin and eosin (H&E) staining. Paracancerous 
control sample tissues were also collected. In addition, 60 primary NSCLC patients without any 
complications were enrolled, and 60 healthy volunteers were enrolled at the same institutions. Serum 
samples of patients were collected, and protein expressions of IL-33, ST2, IL-4, and interferon (IFN)-γ 
were detected by enzyme-linked immunosorbent assay (ELISA) or western blot assay.  
Results: The results indicate that IL-33, ST2 and IL-4 expressions in cancer tissues and blood were 
significantly increased when compared with control groups.  
Conclusion: IL-33/ST2 in NSCLC microenvironment enhances T helper cell 2 (Th2) response, which 
may be beneficial for tumor growth.  
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Lung cancer is the leading cause of cancer 
deaths both in males and females throughout the 
world, including China. It is estimated that the 
incidence and mortality of lung cancer were 
approximately 7.33 and 6.10 % in China in 2015, 
respectively [1]. Non-small cell lung cancer 
(NSCLC) accounts for the majority of lung 
cancers diagnosed at an advanced stage and 
comprises about 85 % of the cases. Efforts to 
improve the poor prognosis of patients with 
NSCLC depend on a better understanding of the 
biology of the cancer [2]. There are few reports 
regarding the molecular features of the tumor 
microenvironment in dynamic conditions, and 
links to inflammation, immunity, and cancer 
remain unclear. In the 19th century, Rudolf 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2018 Xu J, Qiu T, Li X, Zhou Y, Zhou P. This work is licensed under the Creative Commons Attribution 4.0 
International License 
 
Xu et al 
Trop J Pharm Res, May 2018; 17(5): 768 
 
Virchow observed the presence of leukocytes 
within tumors, and suggested a possible link 
between inflammation and cancer [3,4]. 
Persistent Helicobacter pylori infection can cause 
gastric cancer and mucosa-associated lymphoid 
tissue (MALT) lymphoma. Hepatitis B virus 
(HBV) infections increase the risk of 
hepatocellular carcinoma (HCC), and 
Schistosoma or Bacteroides species infections 
have some links with bladder and colon cancer 
[5,6]. Aggarwal argued that about 20 % of 
cancers are associated with chronic infections 
and 30 % are linked to tobacco smoking and 
inhaled pollutants (such as silica and asbestos) 
[7]. Particulate materials and other irritants from 
tobacco can cause chronic obstructive 
pulmonary disease, a condition associated with 
higher lung cancer risk. Inhaled asbestos or silica 
particles also give rise to lung cancer, but have 
no obvious mutagenic effects. COX2 inhibitors, 
aspirin and anti-inflammatory steroids, can 
prevent colon cancer, breast cancer [8], and 
reduce prostate cancer risk, but only in 
individuals who carry a particular polymorphic 
allele which specifies high lymphotoxin 
production [9]. Therefore, tumor-promoting 
inflammation is just a single aspect of cancer 
biology.  
 
In the process of immune surveillance, 
precancerous and malignant cells can express 
“altered self” and “non-self” antigens, and induce 
an immune response, which results in the 
destruction of transformed and malignant cells. 
However, an immune surveillance is not always 
successful, resulting in tumor cells escaping the 
immune surveillance and progressing to cancer. 
Ostrand-Rosenbergs proposed that the immune 
response is a double-edged sword in 
tumorigenesis [10]. T cells can exert both tumor-
suppressive and tumor-promoting effects, as 
determined by their effector functions. Type 1 
CD4+ T cells (Th1 cells) facilitate tissue 
destruction and tumor rejection by providing help 
to cytotoxic CD8+ T cells, while Type 2 CD4+ T 
cells T (Th2 cells) facilitate antibody production 
by B cells and promote tumor progression [11]. In 
the present study, we have shown that IL-33/ST2 
in the NSCLC microenvironment enhanced the 







From January 2014 to December 2015, paraffin-
embedded sections from surgical specimens 
were obtained from 40 patients definitively 
diagnosed with NSCLC by pathological 
examinations. The sections were further 
immunostained with antibodies directed against 
IL-33 and ST2, and inflammatory reactions were 
determined by hematoxylin and eosin (H & E) 
staining. Paracancerous tissues were collected 
as control samples. In addition, 60 primary 
NSCLC patients without any complications were 
enrolled, and 60 healthy volunteers were enrolled 
as the control group. Blood samples were 
collected from the vein and the serum samples 
were separated. Protein expression levels of IL-
33, ST2, IL-4 and IFN–γ were detected by 
enzyme-linked immunosorbent assay (ELISA) or 
western blot assays.  
 
All the patients were required to read and sign an 
informed consent form voluntarily before 
enrollment. All the experimental protocols were 
carried out in accordance with the Declaration of 
Helsinki promulgated in 1964 as amended in 
1996 [12]. Approval by Changzhou Wujin 
People's Hospital (no. CZ 2017-0121) was 
obtained. 
 
H & E and immunohistochemistry staining  
 
Samples were fixed in 4 % formaldehyde, 
embedded in paraffin wax, and processed for 
H&E and immunohistochemical analyses of IL - 
33 and ST2. Noncancerous tissues at least 10 
cm from the tumor were analyzed as control 
samples. Sections (5 μm thick) were cut and 
subsequently hydrated. Endogenous peroxidase 
activity was blocked with 3 % tris hydroxymethyl 
aminomethane-buffered saline for 30 min. 
Immunohistochemistry was performed using 
rabbit anti-human IL-33 antibody (Cloud-Clone 
Corp., Houston, TX, USA) and goat anti-human 
ST2 antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). The negative control involved 
omission of the primary antibody. 
 
Western blotting analysis 
 
Lung cancer tissues were lysed in 
radioimmunoprecipitation assay (RIPA) buffer 
including protease and phosphatase inhibitors, 
and proteins were separated by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS 
- PAGE) and transferred to polyvinylidene 
fluoride (PVDF) membranes. The membranes 
were blocked with skimmed milk, incubated with 
primary antibodies (rabbit anti-human IL - 33 
antibody and goat anti-human ST2 antibody), 
and horseradish peroxidase (HRP)-conjugated 
secondary antibody. β-actin was used as an 
internal control. Specific bands were visualized 
using an ECL - PLUS chemiluminescence 
system. 
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Enzyme-linked immunosorbent assay (ELISA) 
 
Serum samples from each individual were 
collected at the time of diagnosis, before 
chemotherapy, and after second chemotherapy. 
Sera were stored at -70 °C. The optical density 
(OD) values of IL-33, IL-4, and IFN-γ from the 
supernatants of each group were detected after 
being centrifuged, while ST2 was detected from 
centrifuged cells. These proteins were measured 
by a sandwich ELISA kit, according to the 
manufacturer’s instructions. The concentration of 





All data were analyzed using SPSS, version 19.0 
software (SPSS, Chicago, IL, USA), and are 
shown as mean ± standard deviation (SD). 
Statistical differences between groups were 
computed by independent sample t-tests, with p 




Histopathological features of lung cancer 
tissues 
 
IL-33 - positive immunostaining was located in 
tumor cells (adenocarcinoma and squamous cell 
carcinoma), and adjacent normal tissues at least 
10 cm from the tumor were used as normal lung 
tissues (Figure 1 A). In either adenocarcinoma 
(Figure 1 D) or squamous cell carcinoma (Figure 
1 E) tissues, there were many inflammatory and 
immune cells, such as macrophages, 
neutrophils, dendritic cells, and T and B 
lymphocytes with surrounding stroma (consisting 
of fibroblasts, endothelial cells, pericytes, and 
mesenchymal cells). ST2 was immunostained 
positively at the areas of inflammation and 




Figure 1: Hematoxylin-eosin and 
immunohistochemistry staining of lung tissues. A-F 
represented as the paracancer tissues (A), IL-33-
positive cells of adenocarcinoma (B) squamous cell 
carcinoma (C), HE staining tissues of adenocarcinoma 
(D) squamous cell carcinoma (E), ST2 positive 
staining (F) 
 
Expressions of proteins IL-33 and ST2 in 
NSCLC tissue 
 
As can be seen in Figure 2, compared to normal 
lung tissues, the protein levels of ST2 and IL-33 
in NSCLC tissues were significantly upregulated 
(p < 0.05; Figure 2). No other significant 
differences were observed between 





Figure 2: Results of the western blotting of IL – 33 
and ST2. (squamous means squamous carcinoma 
cell). Data were expressed as Mean ± SD; * p < 0.05 
vs paracancer groups (control group) 
 
Serum levels of IL-33, ST2, IL-4, and IFN - γ  
 
As shown in Figure 3, the serum levels of IL-33, 
ST2, and IL-4 of NSCLC patients were 
significantly higher than those in normal lung 
tissues (p < 0.05). In contrast, the IFN-γ levels in 
the serum of NSCLC patients remained lower 
than that of normal lung tissues, but showed no 
statistical differences (p > 0.05). There were no 
significant differences of IL-33, ST2, IL-4, and 
IFN-γ between patients with adenocarcinoma 




Figure 3: Blood levels of IL-33, ST2, IL-4, IFN-γ by 
using ELISA. Data were expressed as Mean ± SD; *p 
< 0.05 vs paracancer groups (control group) 
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IL-33 is a cytokine of IL-1 family, also called IL-
1F11 according to systematic nomenclature. 
Produced as a pro – IL-33, the 31 kDa protein, 
IL-33 is cleaved to form a mature 18 kDa protein, 
which works as a cytokine through its IL-1 
receptor family members [11,12]. ST2, the most 
prominent orphan IL-1 receptor (also designated 
T1, Fit-1, and DER4), belongs to Toll-like 
receptor-IL-1 receptor (TLR-IL-1R) superfamily 
[13-15]. Schmitz et al first identified the orphan 
receptor “ST2” (also called IL-1R4) as a receptor 
for IL - 33. Co-immunoprecipitation demonstrated 
that a combination of IL-33 and ST2 can 
ultimately lead to the activation of NF-κB and 
MAPK kinases involved in the control of cellular 
proliferation and apoptosis [11]. Xu et al have 
shown that ST2 gene products are predominantly 
expressed in Th2 cells but not in Th1 cells, and 
have been recognized as stable markers of Th2 
cells [16,17]. Recently, IL - 33/ST2 signaling has 
been studied in many fibrotic diseases such as 
scleroderma, progressive systemic sclerosis 
[18,19], and liver fibrosis in mice and humans 
[20]. 
 
This study was the first to determine whether IL - 
33/ST2 signaling existed in NSCLC. IL -33 and 
ST2 were analyzed in NSCLC tissues by 
immunohistochemistry, with L - 33 - positive cells 
being tumor cells, while ST2-positive reactions 
were located in inflammatory cells. The greater 
levels of IL-4 and ST2, and the lower level of 
IFN-γ in NSCLC patients’ sera indicated that 
there was a Th1/Th2 imbalance with a striking 
Th2 response in NSCLC. In breast cancer, the 
presence of tumor-infiltrating lymphocytes with 
high CD4+/CD8 + and Th2/Th1 ratios were 
indicative of poor prognoses [21]. Th2 CD4+ T 
cells stimulate mammary cancer progression and 
metastasis by activing tumor-associated 
macrophages (TAMs) to produce proangiogenic 
and pro-metastatic factors [22]. Dunn et al 
proposed that the presence of tumor-infiltrating 
lymphocytes was insufficient for curtailing tumor 
growth, and the cancer cells escaping the 
immune surveillance system were constantly 
edited and modulated by the host antitumor 
immune response [23]. Consistent with this 
hypothesis, it was speculated that tumor cells 
expressing and releasing IL - 33, as a 
proinflammatory mediator, recruited monocytes 
and changed the tumor dynamic 
microenvironment, which consisted of 
macrophages, neutrophils, and T lymphocytes. 
IL-3, as an immune modulator, in combination 
with ST2 of Th2 cells or other cells in the tumor 
microenvironment and NSCLC blood, can 
enhance the Th2 response in favor of tumor 
growth, thus tipping the balance of tumor-




The findings of the present investigation 
demonstrate that activated tumor environmental 
cells provide both anti- and protumorigenic 
signals, which may represent targets to be 
harnessed or attacked for therapeutic 
advantages. In addition, the data also indicate 
that tumor-promoting IL-33 provides a target 
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